AiDrugDev.com is the independent intelligence hub for artificial intelligence in drug discovery and development — tracking the companies, clinical pipelines, partnerships, and data that are reshaping how medicines are found.
Verified market and pipeline data, with sources. Updated August 2026.
The AI-first biotechs and platforms defining the field.
Pharma.AI platform (PandaOmics, Chemistry42, Science42). Rentosertib — the first AI-discovered drug to clear Phase IIa — entered Phase III in July 2026. 40+ pipeline programs, 13 IND approvals. Listed on HKEX in Dec 2025.
65PB multi-omics data, high-throughput CRISPR imaging. Merged with Exscientia (Nov 2024) to combine phenotypic screening with generative chemistry. BioHive-2 supercomputer with NVIDIA.
Google DeepMind spin-out commercializing AlphaFold 3. US$600M Series A (2025). Partnerships with Novartis and Eli Lilly valued at ~US$3B combined. Preparing first oncology trials.
Centaur platform; six AI-designed molecules entered clinical trials. GTAEXS617 (CDK7) in Phase 1/2; EXS4318 licensed to Bristol Myers Squibb.
Hybrid physics-based and machine-learning platform. LiveDesign adopted by BMS (US$2.7B deal), Sanofi, Eli Lilly. FY2024 revenue ~US$190M.
Knowledge-graph + ML target identification with a neurology focus. Long-standing AstraZeneca collaboration.
The moments that matter in AI pharma.
Insilico Medicine's TNIK inhibitor for idiopathic pulmonary fibrosis — the first fully AI-discovered drug to show positive Phase IIa efficacy (published in Nature Medicine, 2025) — advanced into a 320-patient Phase III trial.
AI/ML drug discovery and licensing companies raised US$8.9B across 264 rounds in 2024, then US$11B across 348 rounds in 2025 (DealForma). 2024–2025 partnerships and M&A value exceeded US$55B.
Isomorphic Labs raised US$600M in 2025 to commercialize AlphaFold 3 for drug design, with ~US$3B in combined pharma partnerships (Novartis, Eli Lilly).
NVIDIA partnered with Novo Nordisk (2025) on Gefion supercomputer workloads and BioNeMo, and built BioHive-2 with Recursion — putting AI compute at the center of pharma R&D.
Follow the news, pipeline movements, and market signals.
AI-designed molecules clear Phase I at 80–90%, but Phase II success sits near 40% — statistically on par with conventional development.
The 320-patient study is the first real verdict on whether AI-originated chemistry survives late-stage testing.
Company nominated 6 new preclinical candidates and advanced 8 programs in clinical development during the period.
Eight ministries called for AI-driven new-drug discovery platforms using multimodal efficacy-prediction models.
The largest biotech IPO on the Hong Kong exchange in 2025.
Gefion supercomputer + BioNeMo generative AI for early research and clinical development.
Reach decision-makers across AI drug discovery with banner advertising on AiDrugDev.com.
View Media Kit